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Abstract: The effects of buckwheat intake on cardiovascular diseases (CVDs) have not been
systematically investigated. The aim of the present study was to comprehensively summarize
studies in humans and animals, evaluating the impact of buckwheat consumption on CVD risk
markers and to conduct a meta-analysis of relevant data. Thirteen randomized, controlled human
studies, two cross-sectional human studies and twenty-one animal studies were identified. Using
random-effects models, the weighted mean difference of post-intervention concentrations of blood
glucose, total cholesterol and triglycerides were significantly decreased following buckwheat
intervention compared with controls [differences in blood glucose: −0.85 mmol/L (95% CI: −1.31,
−0.39), total cholesterol: 0.50 mmol/L (95% CI:−0.80,−0.20) and triglycerides: 0.25 mmol/L (95% CI:
−0.49,−0.02)]. Responses of a similar magnitude were seen in two cross-sectional studies. For animal
studies, nineteen of twenty-one studies showed a significant reduction in total cholesterol of between
12% and 54%, and fourteen of twenty studies showed a significant reduction in triglycerides of
between 2% and 74%. All exhibited high unexplained heterogeneity. There was inconsistency in
HDL cholesterol outcomes in both human and animal studies. It remains unclear whether increased
buckwheat intake significantly benefits other markers of CVD risk, such as weight, blood pressure,
insulin, and LDL-cholesterol, and underlying mechanisms responsible for any effects are unclear.
Keywords: buckwheat; CVD risk markers; meta-analysis
1. Introduction
Across the globe, cardiovascular diseases (CVDs) are the leading cause of morbidity and death,
and account for approximately one-third of all deaths around the world [1]. Elevated blood pressure,
raised total cholesterol, low density lipoprotein cholesterol (LDL-cholesterol) and high density
lipoprotein cholesterol (HDL-cholesterol) concentrations are clinically considered as major CVD
risk factors. There are increasing epidemiological studies suggesting that diets rich in whole grains are
linked to a lower risk of CVD and mortality [2–6]. In China, recent changes to traditional diets, which
have shown a dramatic decrease in the amount of whole grain consumption from 104 g/day in 1982 to
24 g/day in 2002, may be a contributory factor for the elevated CVD mortality in this country [6,7].
The pseudo-cereal buckwheat, which belongs to the Polygonaceae family, is included in the “whole
grain” category in terms of nutritional value [8]. Buckwheat has been cultivated as a traditional food in
China since 1000BC and is found almost everywhere globally, but mainly in the northern hemisphere,
such as in Russia and China [9].
In recent years, there has been increasing interest in the use of buckwheat as a raw food material
owing to its “re-discovered” nutritional value and health benefits [9,10]. Among the main nine species
with agricultural significance, common buckwheat and Tartary buckwheat (also known as bitter
buckwheat) are the most widely grown species [11]. Buckwheat seeds are the principle form for
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human consumption, and they are mainly consumed as milled flours used in bakery products (bread,
noodles, snacks and cookies) enriched with buckwheat flour at levels ranging up to 60%, and in
non-bakery buckwheat products (honey, tea and sprouted grains) [12]. In addition to a high starch
content as an energy source, buckwheat is rich in nutritionally valuable protein with a well-balanced
amino acid profile, dietary fibre, lipids and minerals, along with other health-promoting components
such as phenolic compounds and sterols, which have attracted growing attention to buckwheat as
a potential functional food [13]. Buckwheat, as a traditional Chinese foodstuff, is well known to
contain high concentrations of rutin compared with other common plant foods. In addition, the
absence of gluten makes buckwheat-containing products potential alternatives for patients suffering
from celiac disease [14]. It has been demonstrated that intake of buckwheat or buckwheat-enriched
products is associated with a wide range of health benefits, including anticancer, anti-inflammatory,
hypoglycemic and hypocholesterolemic effects, although the specific bioactive components responsible
for the beneficial effects of buckwheat remain uncertain [15].
To date, relatively few studies have been carried out to investigate the impact of buckwheat
intake on human health. Moreover, to our knowledge, there has not been any quantitative study to
systematically review and summarize the effects of buckwheat consumption on CVD risk markers.
With accumulating evidence, the object of this work was to comprehensively review the recent literature
and carry out a meta-analysis evaluating the changes in blood glucose and lipid concentrations
induced by buckwheat intake in humans and animals. A secondary objective was to explore possible
mechanisms underlying any beneficial effects observed.
2. Materials and Methods
2.1. Data Sources and Literature Search
A comprehensive literature search for prospective studies that had evaluated the correlation
between buckwheat intake and CVD risk between 1960 and 2018 was undertaken. PubMed, Scopus,
Ovid, EBSCO, Web of Science, ProQuest databases, Science, JSTOR, Medline and China National
Knowledge Infrastructure were searched using the search terms ‘buckwheat’ AND ‘cardiovascular
disease’ OR ‘cholesterol’ AND ‘human’ OR ‘animal’, and the same terms were applied in each database
during the search phase. CVD was defined to include stroke, aortic disease, peripheral arterial disease
and coronary heart disease. In addition, the reference lists of retrieved papers were searched manually
for all additional potentially relevant papers. The search was restricted to studies on humans and
animals and included those that were written in different languages including English or Chinese.
Data were extracted by a single reviewer.
The studies included in this review met the following criteria: (1) a prospective cohort study,
(2) normal laboratory animals or free living humans, (3) buckwheat-intake exposure, (4) the results
included markers of CVD risk, such as plasma glucose and insulin concentrations and lipid profile.
Since cholesterol was the most common indicator of CVD response to whole-grain foods, cholesterol
was used as a primary outcome marker in this review. The eligibility criteria were set before the start
of the research.
2.2. Data Extraction
The following data were extracted from each human study: lead author, year of publication,
characteristics of subjects, number of subjects, mean/median intake of buckwheat, types of buckwheat
consumed, trial length and findings. The sample size of human studies in this review was the overall
total for the experiment rather than restricting to either control or intervention diet/s. The following
data were extracted from each animal study: lead author, year of publication, animal species,
mean/median intake of buckwheat, experimental diet, trial length and outcomes. Missing data
are reported as “Not stated” if they were not explained in the corresponding articles.
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2.3. Statistical Analysis
All statistical analyses were performed with STATA 12.0 (Stata Corp, College Station, TX, USA);
P < 0.05 was considered significant. Heterogeneity across studies was quantified by using the I2 statistic
to consider each study design, as a quantitative evaluation of inconsistency among studies [16]. To pool
the results of studies of the acute impacts on blood glucose, lipid profiles, a fixed effects model was used
when heterogeneity was absent or low (I2 < 20%); when heterogeneity was greater, a random-effects
model was used. In this review, weighted mean differences (WMDs) between treatment (buckwheat
diet) and control groups (normal or refined diet) or before and after treatment were combined via a
random-effects model to evaluate the size of treatment impacts on CVD risk markers, including blood
concentrations of glucose, total, HDL and LDL cholesterol and triglycerides. To examine whether
a single study exerted undue impact on the overall results, sensitivity analyses were performed in
which each individual study was excluded from the meta-analysis and the effect size recalculated with
the remaining studies. For all outcomes, a priori subgroup analyses were planned to be conducted
with meta-regression models, if there were ≥10 studies. Results of the studies reported in mg/dL
were converted to mmol/L using standard conversion factors, with 1 mg/dL = 0.02586 mmol/L for
cholesterol, 1 mg/dL = 0.01129 mmol/L for triglycerides. These values were obtained as mean ±
SD. For continuous results, summary estimates of WMD with 95% CI were assessed for net changes
between each treatment and control groups. Finally, potential publication bias of the studies was also
evaluated by visual inspection of Funnel plots and quantitatively assessed using Begg’s and Egger’s
tests, where P < 0.05 was deemed statistically significant [17].
3. Results
3.1. Study Selection
As shown in Figure 1, the systematic search of the scientific databases led to the initial
identification of 675 articles for further evaluation. After removing duplicate articles (239) and articles
that did not meet the eligibility criteria (408), a total of 28 articles including 11 human studies and
17 animal studies were included in the review. It was noteworthy that five trials were reported in the
same population; thus, the current review combined the informative data and retained only the latest
paper to avoid information duplication [18–22]. Manual searching of the reference list of the relevant
articles yielded 18 additional articles. After applying the inclusion criteria, eight of these articles
were considered fit to include. Consequently, the combination of electronic and manual searching
resulted in 36 articles which were included in the final review. To be specific, this review pooled
the results of 15 human studies, consisting of 13 short-term randomized, controlled trials (RCT) and
2 cross-sectional studies, which had the assessed lipid-lowering effects of buckwheat in free-living
subjects, and 21 animal studies. Nine human studies were conducted in China, two in India and one
each in Sweden, Canada, Italy and Serbia. Ten animal studies were carried out in Japan, seven in China
and one each in Spain, Poland, Egypt and South Korea.
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Figure 1. Flow diagram of article selection.
3.2. Characteristics of Studies
Extracted data from the human and animal studies are in Tables 1 and 2, respectively. All except
two human cross-sectional studies in the review were RCT studies, with follow-up durations ranging
from 7 days to 24 weeks in human studies and 10 days to 8 weeks in animal studies. Overall, buckwheat
intake in RCT human studies ranged from 40 g to 300 g of buckwheat ingredients (median levels
of individual series), with four studies not stating the amounts consumed. Participants were either
healthy or had one or more CVD risk markers, including overweight, hypertension, hyperglycemia
and hyperlipidemia. The methods of the included studies were similar, with a baseline period which
was followed by su jects or animals being offered buckwheat or buckwheat-based products (e.g.,
buckwhe t bread, buckwheat flour) for consumption, or placebo diets. Blood sampl re obtained
at baseline and after the intervention period for comparison of CVD biomarkers. It should be noted
that outcomes in 12 out of 13 human intervention studies were only compared against baseline, and
one study by Yu [23] was compared against a control group; removal of this study did not affect the
outcomes of meta-analyses so it was retained in the dataset analyzed. Liver or feces were only available
from animal studies. With respect to the two human cross-sectional studies, since the populations
started to consume fairly high amounts of buckwheat seeds as a staple food from an early age, the
outcomes obtained were adjudged as representing the long-term impact of buckwheat grain on CVD
risk markers.
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Table 1. Summary of all human studies reviewed.
Human Studies
Source Study Population Foodstuff; Intake Duration
Outcomes 95% CI
Significant Insignificant
Bijlani et al. (1985)
[24]
healthy (n = 8♂) 100 g of whole BW flour
12 weeks serum: VLDL ↓ body weight
serum: TC
serum: LDL
serum: HDL
serum: HDL/TC
serum: LDLTG
serum: VLDLTG
serum: HDLTG
serum: TG
healthy (n = 9♂) 100 g of whole BW flour
4 weeks serum: HDL/TC ↑ body weight
serum: LDLTG ↑ fasting blood glucose
serum: VLDLTG ↑ glucose
serum: HDLTG ↓ serum: TC
serum: LDL
serum: VLDL
serum: HDL
serum: TG
Bijlani et al. (1984)
[25]
healthy (n = 12♂) 100 g of sieved BW preparation
4 weeks serum: HDL ↑ blood glucose
serum: HDL/TC ↑ serum: TC
serum: LDL
serum: VLDL
Lu et al. (1990) [26]
patients with diabetes
and hyperlipidemia
(n = 23, 13 and 18)
BW flour 1 month fasting blood sugar ↓
BW flour 1 month serum: TC ↓
BW flour 1 month serum: TG ↓
Zheng et al. (1991)
[27]
NIDDM patients
(n = 10♂, 9♀) Tartary BW flour; 50 g
3 months serum: TG ↓ Blood glucose
insulin
serum: TC
Liu and Fu (1996) [28] patients (n = 60) Tartary BW flour; 40 g/day
4 weeks body weight ↓
systolic BP ↓
diastolic BP ↓
serum: TC ↓
serum: LDL ↓
serum: HDL ↑
serum: TG ↓
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Table 1. Cont.
Human Studies
Source Study Population Foodstuff; Intake Duration
Outcomes 95% CI
Significant Insignificant
Lin et al. (1998) [29] Type 2 diabetes (T2DM)
(n = 32)
100 g of Tartary BW flour
5 weeks fasting blood ↓ serum: TC
glucose
serum: TG ↓
Zhao and Guan (2003)
[30]
T2DM (n = 30♂, 30♀) BW flour
8 weeks blood glucose ↓ body weight
systolic BP ↓ diastolic BP
serum: TC ↓ serum: LDL
serum: HDL ↓ serum: TG
Huang et al. (2009)
[31]
patients with diabtes
(n = 18♂, 17♀) Tartary BW mixture 2 months
blood glucose ↓
HbA1 c/% ↓
serum: TC ↓
serum: LDL ↓
serum: HDL ↓
serum: TG ↓
Wieslander et al.
(2011) [32]
healthy (n = 62♀)
group 1: four common BW
cookies (daily).
group 2: four Tartary BW
cookies (daily).
(after 2 weeks wash-out, the
groups switch type of cookies)
100 g of sieved BW preparation
6 weeks serum: TC ↓ sPLA2
serum: HDL ↓
Stringer et al. (2013)
[33]
healthy (n = 23) BW cracker; 76 g
7 days plasma glucose
plasma: TC
plasma: LDL
plasma: HDL
plasma: TG
liver enzyme AST
liver enzyme ALT
T2DM (n = 24) BW cracker; 76 g
7 days plasma glucose
plasma: TC
plasma: LDL
plasma: HDL
plasma: TG
liver enzyme AST
liver enzyme ALT
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Table 1. Cont.
Human Studies
Source Study Population Foodstuff; Intake Duration
Outcomes 95% CI
Significant Insignificant
Stokic´ et al. (2015)
[34]
patients (n = 7♂, 13♀) BW-enriched wheat bread;
300 g/day
1 month serum: TC ↓ BMI
serum: LDL ↓ systolic BP
liver enzyme AST ↑ diastolic BP
liver enzyme ALT ↓ serum: HDL
serum: TG
Yu (2015) [23]
patients with
hyperlipidemia
(n = 36♂, 24♀)
Tartary BW tea, 15 g
60 days serum: TC ↓ systolic BP
serum: LDL ↓ diastolic BP
serum: TG ↓ blood glucose
serum: HDL
Dinu et al. (2017) [35] participants with high
CVD risk (n = 10♂, 11♀)
group 1: BW products (daily);
group 2: control products (daily)
(after 8 weeks wash-out, the
groups switch type of products)
24 weeks fasting blood glucose ↓ body weight
glucose insulin
serum: TC ↓ serum: HDL
serum: LDL ↓
serum: TG ↓
He et al. (1995) [36] healthy (n = 857♂)
BW;
group 1 (n = 319), 0 g/day
group 2 (n = 207), <40 g/day
group 3 (n = 161), 40–200 g/day
group 4 (n = 163), >200 g/day
cross-sectional study
systolic BP ↓ BMI
diastolic BP ↓ serum: HDL
serum: TC ↑ serum: TG
serum: LDL ↓
serum: HDL/TC ↓
Zhang et al. (2007)
[18]
healthy (n = 491♂, 470♀) BW; not stated cross-sectional study
BMI ↑ systolic BP
blood glucose ↓ diastolic BP
serum: TC ↓ serum: TG
serum: LDL ↓
serum: HDL ↑
BW, buckwheat; VLDL, very low-density lipoprotein; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; BP, blood pressure; HbA1 c,
glycated hemoglobin A1c; sPLA2, secretory phospholipase A2; AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index.
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Table 2. Summary of all animal studies reviewed.
Animal Studies
Source Model Assay Product; Dose Duration
Outcomes 95% CI
Significant Insignificant
Son et al. (2008) [37] ♂Sprague–Dawley rats BW powder; 50% in the diets (diet
with 1% cholesterol)
4 weeks plasma: TC ↓ food intake
plasma: LDL ↓ body weight gain
plasma: HDL ↑ food efficiency ratio
plasma: TG ↓ transit time
area of lumen ↑ wall thickness
Yang et al. (2014) [38] ♂Syrian Golden hamster Tartary BW flour; 24% in diet (fed
cholesterol diet)
6 weeks serum: TC ↓ food intake
serum: non-HDL ↓ body weight gain
liver cholesterol ↓ serum: HDL
feces: neutral sterols ↑ serum: TG
feces: acidic sterols
Prestamo (1985) et al.
[39]
♀Wistar Hannover rats
cooked BW 30 days body weight ↓ blood glucose
serum: TC ↓ serum: LDL
serum: HDL ↓ serum: TG
HDL phospholipids ↓ liver weight
uric acids
Orzel et al. (2015) [40] ♂Wistar rats buckwheat flour, meal and bran;200 g/kg (normal diet)
4 weeks body weight gain ↑ food intake
serum: LDL ↓ glucose
serum: TG ↓ hemoglobin
serum: TC
serum: HDL
Tomotake et al. (1985)
[41]
♂Sprague–Dawley rats and♂ddY mice
30.7% of BWP extract in the diet (rats
fed a normal or high-cholesterol diet);
54.8% of PBF (mice fed a
high-cholesterol diet)
10 or 27 days serum: TC ↓ food intake
serum: TG ↓ body weight gain
serum: phospholipids ↓
liver weight ↓
liver cholesterol (PBF) ↓
feces: dry weight (PBF) ↑
feces: neutral steroids ↑
feces: bile acids (PBF) ↑
Magdy et al. (2014)
[42] ♂albino rats
BW hull extracts; 1000 mg/kg b.
wt/day in diet
(hypercholesterolemia-induced diet)
8 weeks blood glucose ↓ plasma: HDL
plasma: TC ↓
plasma: LDL ↓
plasma: TG ↓
plasma: AST ↓
plasma: ALT ↓
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Table 2. Cont.
Animal Studies
Source Model Assay Product; Dose Duration
Outcomes 95% CI
Significant Insignificant
Wang et al. (2009) [43] ♂pathogen-free Wistar rat Tartary BW bran extract; 0.2–1 g/kg
body weight (high-fat diet)
6 weeks serum: TC ↓ body weight gain
serum: HDL (low dose) ↑ serum: LDL
serum: TG ↓
hepatic: TC ↓
hepatic: TG ↓
Hosaka et al. (2014)
[44]
KK-Ay mice common BW bran powder; 0.05 mg/g
body weight
6 weeks body weight gain ↓ food intake
serum: TG ↓ fasting blood glucose
liver weight ↓ insulin resistance
serum: TC
Yao et al. (2008) [45]
♂C57BL/6 control mice and
diabetic KK-Ay mice
D-Chiro-Inositol (DCI) enriched
Tartary BW bran extract (TBBE);
45–182 mg of TBBE/kg in diet
5 weeks fasting blood glucose level ↓ body weight gain
plasma: TG (high dose) ↓ plasma: TC
Insulin immunoreactivity ↑
immunoreactivity
Hu et al. (2015) [46] ♂Kunming mice
D-Chiro-Inositol (DCI) enriched
Tartary BW extract (DTBE); 40, 80 and
160 mg per kg body weight/day
(high-fructose water)
8 weeks body weight gain ↓
all parameters in the group
of 40 mg per kg body
weight/day showed on
significant effect except
serum AST activity
serum: glucose ↓
serum: insulin level ↓
serum: TC ↓
serum: LDL ↓
serum: HDL ↑
serum: TG ↓
liver weight ↓
serum AST activity ↓
serum ALT activity ↓
Tomotake et al. (2000)
[47]
♂Golden Syrian hamster BWP extract; 381 g/kg
(high-cholesterol diet)
2 weeks food intake ↑ body weight gain
plasma: TC ↓ hepatic TG
plasma: HDL ↓
hepatic phospholipidsplasma: HDL/TC ↑
plasma: TG ↓
plasma: phospholipids ↓
liver weight ↑
hepatic cholesterol ↓
fecal dry weight ↑
feces: neutral steroids ↑
feces: acidic steroids ↑
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Table 2. Cont.
Animal Studies
Source Model Assay Product; Dose Duration
Outcomes 95% CI
Significant Insignificant
Tomotake et al. (2007)
[48]
♂Sprague–Dawley rats
Tartary BW flour protein and common
BWP extract; 30.7% of common BWP
and 43.7% of Tartary BWP in the diet
(high-cholesterol diet)
27 days serum: TC ↓ body weight gain
liver weight ↓ food intake
hepatic cholesterol ↓
fecal dry weight ↑
fecal excretion: nitrogen ↑
feces: neutral steroids ↑
feces: bile acids ↑
protein digestibility ↓
Tomotake et al. (2001)
[49]
♂Sprague–Dawley rats BWP extract; 307 g/kg (normal diet)
8 weeks plasma: TC ↓ body weight gain
plasma: HDL ↓ food intake
feces: neutral steroids ↑ plasma: TG
feces: acidic steroids ↑ plasma: phospholipid
feces dry weight
Kayashita et al. (1997)
[50]
♂Sprague–Dawley rats BWP extract; 381 g/kg
(high-Cholesterol diet)
3 weeks
plasma: TC ↓ body weight gain
plasma: HDL/TC ↑ food intake
plasma: TG ↓ plasma: HDL
plasma: phospholipids ↑ hepatic: TG
plasma: bile acids ↓ feces: acidic steroids
liver weight ↓
hepatic cholesterol ↓
hepatic: phospholipids ↓
feces dry weight ↑
feces: neutral steroids ↑
protein digestibility ↓
Kayashita et al. [51] ♂Sprague–Dawley rats BWP extract; 38.1%
3 weeks plasma: TC ↓ body weight gain
plasma: HDL/TC ↑ food intake
plasma: TG ↓ plasma: HDL
plasma: free fatty acid ↓ hepatic cholesterol
plasma: phospholipids ↓ hepatic TG
liver weight ↓ hepatic phospholipids
fat pad weights ↓
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Table 2. Cont.
Animal Studies
Source Model Assay Product; Dose Duration
Outcomes 95% CI
Significant Insignificant
Kayashita et al. [52] ♂Sprague–Dawley rats BWP extract; 381 g/kg
3 weeks plasma: TC ↓ body weight gain
hepatic TG ↓ food intake
fecal dry weight ↑ insulin
fat pad weights ↓ plasma: TG
plasma: free fatty acid
plasma: phospholipids
liver weight
hepatic TC
hepatic phospholipids
Kayashita et al. [53] ♂Sprague–Dawley rats BWP extract; 323.1 g/kg
(high-Cholesterol diet)
3 weeks plasma: TC ↓ body weight gain
hepatic: weight ↓ food intake
hepatic TC ↓ serum: TG
hepatic TG ↑ serum: free fatty acids
serum: glucose
Hu et al. [54] ♂Kunming mice Tartary buckwheat flavonoid fraction;200, 400 and 800 mg per kg bw in diet
(high trimethylamine-N-oxide diet)
8 weeks body weight gain ↓ food intake
serum: TC ↓ water intake
serum: LDL ↓
serum: HDL ↑
serum: TG ↓
liver weight ↓
hepatosomatic index ↓
Han et al. [55] Wister mice
total flavones of buckwheat seeds;
2 g/kg/day (high-fat diet)
10 days serum: TC ↓ fasting blood glucose
serum: TG ↓
Qu et al. [56] ♂Sprague–Dawley rats high rutin in BW noodles; 980 mg/kgin diet (high-fat, high-sucrose diet)
4 weeks serum: TC ↓ body weight gain
liver lipid ↑ feed efficiency
serum: HDL
serum: TG
serum: free fatty acids
liver TC
dry weight of feces
fecal total lipid
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Table 2. Cont.
Animal Studies
Source Model Assay Product; Dose Duration
Outcomes 95% CI
Significant Insignificant
Zhang et al. [57]
♂Golden Syrian
Hypercholesterolemia
hamster
Tartary BWP extract; 353 g/kg in diet
6 weeks plasma: TC ↓ body weight
plasma: non-HDL ↓ fatty streak (%)
plasma: HDL ↓
plasma: TG ↓
liver cholesterol ↓
total neutral sterols ↑
acidic sterols ↑
BW, buckwheat; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; BWP, buckwheat protein; PBF, protein buckwheat flour; AST,
aspartate transaminase; ALT, alanine transaminase.
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3.3. Human Studies
3.3.1. Effects on Body Weight and BMI
Body weight or BMI changed significantly in response to buckwheat consumption in two out
of seven human studies but in contrasting ways (Table 3). Body weight decreased by 3.44 kg among
44 overweight participants in one of the studies by Liu and Fu, while BMI was higher (estimated
3%) in consumers of buckwheat than in non-consumers in the study of Zhang and colleagues [18,28].
The other studies observed no significant impact of buckwheat consumption on body weight or BMI.
Table 3. The number of animal and human intervention studies showing significant increase, no effect
and significant reduction on markers of CVD risk.
Number of Studies
Significantly higher in
Buckwheat Treatment No Effect
Significantly Lower in
Buckwheat Treatment
Human Studies
Body weight gain or BMI 1 5 1
Blood pressure — 3 3
Blood glucose — 5 6
Blood insulin — 2 —
Total-Cholesterol — 5 10
LDL-Cholesterol — 4 7
HDL-Cholesterol 3 6 3
Triglycerides — 6 7
Animal Studies
Body weight gain 1 14 4
Food intake 1 12 —
Blood glucose — 4 3
Blood insulin 1 2 1
Total-Cholesterol — 2 19
LDL-Cholesterol — 2 5
HDL-Cholesterol 4 6 4
Triglycerides — 6 14
Liver weight 1 2 8
Liver Total-Cholesterol — 3 8
Fecal weight 5 2 —
Fecal neutral steroids 6 — —
3.3.2. Effects on Blood Pressure
The association between buckwheat intake and blood pressure yielded inconsistent results. Of six
human studies which evaluated blood pressure, He and colleagues found that in those who consumed
≥40 g buckwheat/day, blood pressure was lower compared with those who consumed none or <40
g/day [36]. A significant reduction was also observed in hypertensive participants in the study
conducted by Liu and Fu [28]. In a further study, systolic blood pressure was significantly decreased
relative to the baseline, whereas diastolic blood pressure was only slightly, and not significantly lower
in type 2 diabetic subjects [30]. For the remaining three human studies, there were no significant
changes in blood pressure in response to intake of buckwheat-based foods.
3.3.3. Effects on Blood Glucose and Insulin
Data on fasting blood glucose concentrations were reported in nine randomized, controlled trials
representing 548 participants based on the results of the meta-analysis. Figure 2 shows the pooled
results from the random-effects model combing the weighted mean difference (WMD) for the impact
of buckwheat intake on fasting glucose concentration in the total study population. The results
Nutrients 2018, 10, 619 14 of 29
show that the fasting blood glucose concentration was significantly decreased with buckwheat
treatment in comparison with baseline or control groups (WMD, −0.85 mmol/L; 95% CI: −1.31,
−0.39; P < 0.001), with significant heterogeneity in the data (I2 = 94.2%). This finding is consistent with
the result of Zhang and colleagues, who showed that fasting blood glucose concentration of people
in a buckwheat-eating region of Mongolia was significantly lower (16.92%) than that of people in a
non-buckwheat-eating region of the country [18]. There was no consistent effect of buckwheat on
insulin concentrations reported, with a small non-significant reduction and a small non-significant
increase in insulin concentrations reported in two studies [27,35].
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Figure 2. Meta-analysis of the effects of buckwheat products intake on blood glucose concentration
compared with baseline or control groups for human studies. Sizes of data markers indicate the
weight of each study in the analysis. WMD, weighted mean difference (the results were gained
from a random-effects model). Negative values favor a reductio in blood glucose with buckwheat
consumption; the dashed line shows the overall WMD value and the size of the rhombus the cumulative
effect size and CI.
3.3.4. Effect on Lipid Profile
Results from the random-effects meta-analysis of the association between buckwheat intake and
lipid parameters are shown in Figures 3–6. Compared with baseline or control arms, buckwheat
consumption was associated with statistically significantly lower concentrations of total cholesterol
(WMD, −0.50 mmol/L; 95% CI: −0.80, −0.20; 12 trials, 708 participates, I2 = 89.5%, P = 0.001) and
triglycerides (WMD, −0.25 mmol/L; 95% CI: −0.49, −0.02; 11 trials, 592 participates, I2 = 92.5%,
P = 0.034). However, there were no significant effects on LDL-cholesterol (WMD, −0.33 mmol/L;
95% CI: −0.66, −0.02; 9 trials, 520 participates, I2 = 95.3%, P = 0.061) after buckwheat intake, nor on
HDL-cholesterol (WMD, −0.09 mmol/L; 95% CI: −0.25, −0.07; 10 trials, 642 participates, I2 = 94.4%,
P = 0.282).
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Figure 3. Meta-analysis of the effects of buckwheat products intake on blood total cholesterol
concentration compared with baseline or control groups for human studies. Sizes of data markers
indicate the weight of each study in the analysis. WMD, weighted mean difference (the results were
gained from a random-effects model). Negative values favor a reduction in blood total cholesterol with
buckwheat consumption; the dashed line shows the overall WMD value and the size of the rhombus
the cumulative effect size and CI.
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Figure 4. Meta-analysis of the effects of buckwheat products intake on blood LDL cholesterol
concentration compared with baseline or control groups for human studies. Sizes of data markers
indicate the weight of each study in the analysis. WMD, weighted mean difference (the results were
gained from a random-effects model). Negative values favor a reduction in blood LDL cholesterol with
buckwheat consumption; the dashed line shows the overall WMD value and the size of the rhombus
the cumulative effect size and CI.
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Figure 5. Meta-analysis of the effects of buckwheat products intake on blood HDL cholesterol
concentration compared with baseline or control groups for human studies. Sizes of data markers
indicate the weight of each study in the analysis. WMD, weighted mean difference (the results were
gained from a random-effects model). Negat v values fav r a reduction in blood HDL Cholesterol
with buckwheat onsumption; he dashed line shows the overall WMD value and the size of the
rhombus the cumulative effect size and CI.
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Figure 6. Meta-analysis of the effects of buckwheat products intake on blood triglycerides concentration
compared with baseline or control groups for human studies. Sizes of data markers indicate the
weight of each study in the analysis. WMD, weighted mean difference (the results were gained from
a random-effects model). Negative va ues favor a reduction in blood triglycerides with buckwheat
consumption; the dashed line shows the overall WMD value and the size of the rhombus the cumulative
effect size and CI.
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In the cross-sectional study of 857 Yi men conducted by He and colleagues, after
multiple-regression analysis, buckwheat intake (100 g/day) was associated with significantly lower
concentrations of serum total cholesterol (−0.07 mmol/L, P < 0.01), LDL-cholesterol (−0.06 mmol/L,
P < 0.05) and a higher ratio of HDL to total cholesterol (0.01, P < 0.05), with no effect on HDL-cholesterol
and triglycerides [36]. These findings were in general accordance with the results from the trial
by Zhang and colleagues with 961 participants, which also identified a significant decrease in
HDL-cholesterol by 0.10 mmol/L (P < 0.01) [18].
3.3.5. Sensitivity Analyses and Subgroups Analyses
In sensitivity analyses, after systematically removing individual studies, the beneficial pooled
effects of buckwheat consumption on total cholesterol concentration were retained. However, the
effect on triglycerides was no longer significant after removal of the study that had the largest effect on
the overall result [31]. In contrast, the effect on LDL-cholesterol became statistically significant after
the study that had the largest negative effects on the overall result was excluded [24]. No effects on
glucose and HDL-cholesterol were observed when individual studies were removed (data not shown).
Subgroup analyses were planned a priori to investigate whether study duration, buckwheat dose,
types of buckwheat and study design altered the effects of buckwheat on glucose and lipid profiles,
but the ability to do this was effectively hindered by the small numbers of studies for each trial, since
meta-regression requires ≥10 studies per factor examined [58].
3.3.6. Publication Bias
Funnel plots of the meta-analysis of the effect of buckwheat intake on glucose and lipid
concentrations are shown in Figure 7. For glucose, Begg’s test P = 0.058, Egger’s test P = 0.130;
for TC, Begg’s test P = 1.000, Egger’s test P = 0.089; for LDL, Begg’s test P = 1.000, Egger’s test P = 0.891;
for HDL, Begg’s test P = 0.474, Egger’s test P = 0.720; TG, Begg’s test P = 0.350, Egger’s test P = 0.080)
(Figure 7). Begg’s test and Egger’s test were not significant (P > 0.05), indicating that there was no
evidence of publication bias.
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3.4.2. Effects on Blood Glucose and Insulin 
Three out of seven studies reported here showed a significant reduction in glucose concentration 
by between 15.2% and 18.4% (from 0.97 to 1.81 mmol/L), with the remaining studies showing that 
glucose concentration was unaffected by buckwheat treatment. With respect to blood insulin, insulin 
immunoreactivity was enhanced in one study, while a significant reduction in insulin concentration 
was observed in another study, and the two remaining studies found no significant changes.  
3.4.3. Effects on Lipid Profile 
Of the twenty-one animal studies reported here, all investigated the impact of buckwheat intake 
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from 19.6% to 54.6% (from 0.20 to 0.36 mmol/L) in four out of fourteen studies that reported this 
biomarker, while the level decreased (by between 11.5% and 28.4%) in another four studies. Of 
twenty animal studies analyzing the effect on triglycerides, all studies reported that intake of 
buckwheat consumption resulted in a fall in the serum concentration of triglycerides, which fell 
significantly (P < 0.05) from 2.3% to 73.9% (from 0.04 to 2.09 mmol/L) in fourteen studies. 
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Figure 7. Publication bias f nel plots. Tests for publication bias of effe ts of buckwheat intake
on (a) glucose, (b) total cholesterol (c) LDL cholesterol, (d) HDL cholesterol and (e) triglycerides.
The funnel lines represent pseudo-95% confidence intervals; the size of the circles represent the weight
of each study in the analysis. p-values (>0.05 for each plot) were derived from quantitative assessment
of publication bias by Begg’s test and Egger’s test.
3.4. Animal Studies
Because of the variability between species and study designs, data from animal studies were not
pooled for meta-analysis but summarized below.
3.4.1. Effects on Weight Gain and Food Intake
This review contains nineteen animal studies which reported the impact of buckwheat intake on
body weight of which only four reported a significant decrease following buckwheat consumption,
whereas one found a significant increase in body weight by 21.7% compared with the control [40].
With respect to the amounts of food consumed by the animals, food intake did not change significantly
compared with that of the control group in twelve out of thirteen studies, while a marked increase in
food intake wa bserved in the study by Tomotake and colleagues [47].
3.4.2. Effects on Blood Glucose and Insulin
Three out of seven studies reported here showed a significant reduction in glucose co centration
by betwee 15.2% and 18.4% (from 0.97 to 1.81 mmol/L), with the remai ing studies showing that
glucose concentration was unaffected by buckwheat treatment. With respect to blood insulin, insulin
immunoreactivity was enhanced in one study, while a significant reduction in insulin concentration
was observed in another study, and the two remaining studies found no significant changes.
3.4.3. Effects on Lipid Profil
Of the twenty-one animal studies reported here, all investigated the impact of buckwheat intake
on total cholesterol and seven reported results for LDL-cholesterol. Nineteen (90.5%) of the studies
observed a significant reduction in total cholesterol and five (71.4%) of the studies bserved a significant
reduction in LDL cholester l; the remainder identified no significant r sponse. The significant decrease
ranged from 11.7% to 54.1% (from 0.32 to 1.86 mmol/L) for total cholesterol and from 16.2% to 57.8%
(from 0.22 to 1.24 mmol/L) for LDL-cholesterol. HDL cholesterol level increased from 19.6% to 54.6%
(from 0.20 to 0.36 mmol/L) in four out of fourteen studies that reported this biomarker, while the level
decreased (by between 11.5% and 28.4%) in another four studies. Of twenty animal studies analyzing
the effect on triglycerides, all studies reported that intake of buckwheat consumption resulted in a fall
in the serum concentration of triglycerides, which fell significantly (P < 0.05) from 2.3% to 73.9% (from
0.04 to 2.09 mmol/L) in fourteen studies.
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3.4.4. Other Outcomes
The liver weight of animals fed buckwheat food decreased significantly from 8.5 to 19.2% relative
to the comparison group in eight out of eleven studies, while only one showed a significant increase
by 5.4%. Eight of eleven studies found a reduction in liver total cholesterol content (P < 0.05), but no
significant changes were detected in the other three studies. There was a significant increase in fecal
weight and in fecal neutral steroids content by 57.6–171.0% and by 68.8–142.4% in five out of seven
studies and all six studies, respectively.
4. Discussion
4.1. Effects on Body Weight
Being overweight brings about an elevated risk of health problems such as insulin resistance,
type 2 diabetes mellitus, hypertension, hyperlipidemia and cardiovascular disease [59–62]. In order to
evaluate the impact of buckwheat intake on body weight, the overall energy and macronutrient content
in diets offered/consumed should be considered, but this was beyond the scope of this study. However,
as mentioned above, there were few human and animal studies showing a significant reduction in body
weight gain compared with baseline or control in response to consuming buckwheat-based food(s);
restricted energy intake or intention to lose weight was not an intention of the studies reported.
Even though a significant reduction was observed in the study by Liu and colleagues, it must be
noted that the participants involved in the study were overweight, and so body weight loss would
not have been unexpected in an intervention study simply by engaging in the dietary intervention
study itself [28]. Thus, on the basis of the published literature, it seems that the beneficial effects of
buckwheat intake were not associated with weight loss, and this lack of association was consistent in
both humans and animals with a variety of dietary levels of buckwheat or various forms of buckwheat
products provided.
4.2. Effects on Blood Pressure
It is well known that hypertension is considered to be an important CVD risk factor, since half
of ischemic heart disease and 60% of stroke cases are attributable to increased blood pressure [63,64].
One previous study revealed that 12 weeks intervention with whole grain (oats or oats with wheat)
significantly lowered systolic blood pressure compared with a refined cereals group [65]. The effects of
whole grain cereals on blood pressure, however, are inconsistent in comparison with observational
data as reported by Seal and Brownlee and the paper from Tighe and colleagues is the only one to
report a reduced blood pressure in a whole grain intervention that was not based on weight loss [65,66].
A significant reduction in blood pressure was only observed in one of the human studies reported
here conducted by He and colleagues; these authors pointed out that water-soluble fibre, but not total
dietary fibre, was independently associated with blood pressure and so an effect of buckwheat which
has higher levels of soluble fibre than insoluble fibre is a possibility [36]. However, given the small
number of studies carried out to date, this review is not adequately powered to conclude whether or
not there are beneficial effects of buckwheat intake on blood pressure.
4.3. Effects on Blood Glucose and Insulin
Hyperglycaemia and insulin resistance are closely correlated to the risk of developing CVD [67,68].
There is considerable evidence showing that whole grain intake is associated with decreased glucose
concentrations and is inversely associated with insulin resistance, suggesting that it is possible to
regulate glucose and insulin homeostasis by cereal foods and their constituents [69–71]. Buckwheat
is regarded as a low glycemic index (GI) food, and it has been demonstrated that low-GI diets
significantly improved lipid profiles in medium- and long-term treatments, particularly with respect
to decreasing both total and LDL cholesterol concentrations [72–74]. The results of animal studies
with respect to the impact of buckwheat intake on glucose concentration, however, are conflicting,
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suggesting that results from animal studies do not strongly support the beneficial effects and may
not be comparable to humans. In contrast, the meta-analysis of nine clinical trials indicated that diets
supplemented with buckwheat were associated with a significant 0.85 mmol/L decrease in blood
glucose concentration (P < 0.001). Of the many possible mechanisms responsible for modulating blood
glucose concentrations, buckwheat is well known for containing various bioactive phytochemicals
(such as various polyphenols and d-chiro-inositol), which have been shown to positively affect either
glucose or insulin metabolism in animal models [75–78]. In addition, one study showed that the
presence of resistant starch in buckwheat and buckwheat products contributed to its low glycemic
index [79]. As for blood insulin, both human and animal studies yielded inconsistent results for the
association between buckwheat intake and fasting blood insulin concentrations, indicating that there is
no support for a beneficial effect of buckwheat on blood insulin or insulin-mediated glucose responses.
4.4. Effects on Lipid Profile
Cholesterol, produced in the liver and absorbed though the diet, is essential for all animal life in
normal metabolic process. However, observational epidemiologic studies report that risk of heart attack
in subjects with hyperlipidemia is three times higher than those in the general population with normal
lipid status, while a 1% reduction in serum total cholesterol is strongly correlated with a 3% decrease in
CVD risk [80,81]. Thus, treatments which are aimed at reducing cholesterol concentrations are effective
in decreasing death risk from stroke and coronary heart disease. Consistent with two cross-sectional
studies, this meta-analysis of the RCT studies indicated that increased intake of buckwheat-based
products from 7 days to 27 weeks significantly improved an individual’s lipid profile, on average,
decreasing total cholesterol by 0.50 mmol/L and triglycerides by 0.25 mmol/L. Moreover, the beneficial
effects seen in human studies were also supported by strong evidence from animal studies, decreasing
total cholesterol from 0.32 to 1.86 mmol/L and triglycerides from 0.04 to 2.09 mmol/L. Even though the
change in LDL-cholesterol concentration was not statistically different (P = 0.061), the data approached
statistical significance, and the mean reduction was 0.33 mmol/L, and significant decreases were
also observed in two cross-sectional studies. It has been well known that a 1 mmol/L reduction of
LDL-cholesterol lowers the morbidity and mortality of CVD patients by 22%, so a reduction of this
magnitude could have significant clinical effects [82]. No effects of HDL-cholesterol were detected
in the meta-analysis of RCT studies for buckwheat intake, in combination with inconsistent results
from animal studies. The results of the meta-analysis were seen in both healthy and “at risk” subjects,
but it is not possible within this review to examine differences in response between healthy and “at
risk” subjects because of lack of power and the limited number of studies available. Nevertheless, it
should be noted that one meta-analysis which investigated the effect of oats and oat-based products
on lipid biomarkers, demonstrated that greater reductions were observed in studies where subjects
initially had higher total cholesterol concentrations (>5.9 mmol/L) [83]. Thus, there was an indication
that observed effects were generally more marked in subjects with higher CVD risk.
4.5. Buckwheat Intake Levels
Any evaluation of health benefits associated with food products should include an attempt to
define optimal amounts for human consumption. The study of Liu and Fu, described in Table 1,
showed that 40 g/day Tartary buckwheat flour for 4 weeks significantly lowered total cholesterol, LDL
cholesterol and triglycerides concentrations compared with baseline [28]. The dose needed to reach
a significant effect was similar to that of a large population-based study by He and colleagues, who
found that buckwheat intake (≥40 g/day) was inversely related to markedly lower lipid profiles in
comparison with those who consumed less than 40 g buckwheat/day [36]. Stringer and colleagues
found that a higher amount of buckwheat cracker (containing buckwheat 76 g/day) for a shorter time
period (7 days) did not significantly affect lipid profiles when compared with baseline, and similar
results were also observed in two studies with longer intervention periods (4 and 12 weeks) by Bijlani
and colleagues in 1984 and 1985 [24,25,33]. Studies showing the specific amount of buckwheat used are
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scarce, and more well-designed dose–response studies are required to confirm the minimum amounts
of buckwheat needed to have a beneficial effect.
4.6. Bioactive Compounds Responsible for Lipid-Lowering Activity
The lipid-lowering activity of buckwheat has been ascribed to its nutritional composition
including soluble fibre, protein, rutin and quercetin. However, due to the complexity of this
composition, it is difficult to explore potential mechanisms underlying the beneficial effect of
buckwheat on CVD risk. Some have been proposed but not fully explained, and it is possible that a
combination of these components have contributed to the effects, instead of a single factor. As remarked
previously, buckwheat is a good source of dietary fibre (5–11%), particularly the soluble fraction, which
may help lower total cholesterol concentrations in the body [11,84,85]. The cross-sectional study by He
and colleagues demonstrated that both total dietary and water-soluble fibre from buckwheat were
significantly and independently correlated with lower serum total cholesterol concentrations, even
though the average cholesterol concentration was low in the study population [36]. This result was
in agreement with the results showing a similar correlation between water-soluble fibre and serum
total cholesterol [37]. The cholesterol-lowering effects of soluble fibre may be accounted for by several
mechanisms. It has been proposed that soluble fibre binds strongly to bile acids in the small intestine
and elevates fecal bile acids excretion. The loss of bile acids in the stool stimulates the liver to increase
cholesterol uptake from the circulation to replenish the bile acid supply. It also lowers the availability
of bile acids for optimal fat digestion and absorption [86–89]. In addition, soluble fibre delays gastric
emptying, slowing access of nutrients to digestive enzymes and to absorptive surfaces of the small
intestine [90]. In addition, there is also emerging evidence that soluble fibre and resistant starch
are additionally fermented by some bacteria in the colon, producing short-chain fatty acids (SCFA)
perhaps via the inhibition of hepatic cholesterol synthesis in the liver, which helps to lower cholesterol
concentrations [91,92]. One other mechanism that contributes to the cholesterol-lowering effects may
be due to the low glycemic index of buckwheat in humans with the presence of resistance starch in
the cereal [79,93]. However, the hypocholesterolemic effect of buckwheat starch, which was extracted
from buckwheat flour, was not detected in rats when compared with corn starch [47].
It has been generally recognized that plant proteins may reduce plasma cholesterol concentrations,
and the underling mechanisms of the cholesterol-lowering properties of plant proteins have been
extensively analyzed [94–96]. However, in most studies, the effect of plant dietary proteins has
focused on soybean protein, leading to limited information on the influence of other plant proteins and
buckwheat proteins specifically on cholesterol metabolism. Despite having a relatively low digestibility,
buckwheat protein, which accounts for 10% to 12.5% of flour weight, is an excellent supplement to
other common grains, as it contains a good balance of amino acids with high nutritional value [9,97–99].
Previous studies have demonstrated a potent hypocholesterolemic activity of isolated buckwheat
protein products prepared from buckwheat flour in rats or hamsters fed cholesterol-enriched or
cholesterol free diets, which appeared to be stronger than that of soy protein isolate [47–53]. One study
by Kayashita and colleagues further suggested that suppressive effects on cholesterol were mediated
by enhanced excretion of fecal neutral sterols and that lower digestibility of buckwheat protein
products is at least in part responsible for the effect. The lower digestibility may result in lower
gastrointestinal transit time, which in turn leads to a higher stool weight and greater fecal excretion of
neutral sterols. It has been observed that fecal excretion of neutral sterols was inversely correlated with
serum cholesterol (r = −0.83, P < 0.01) [48]. Taken together, these impacts on rats appear to be similar
to the properties of dietary fibre in humans [100,101]. To demonstrate this, Kayashita and colleagues
also performed another experiment showing that plasma cholesterol in rats fed intact buckwheat
protein products for two weeks was significantly lower than that in rats fed trypsin-digested protein.
Moreover, this hypothesis has confirmed that, in the human body, the digestibility of buckwheat
seed proteins was relatively low, owing possibly to the existence of phytic acid, tannins and protease
inhibitors [102]. However, this seemed to contrast with the results that Tartary buckwheat had a
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reduced cholesterol-lowering impact on rats compared with common buckwheat, even though the
digestibility of Tartary buckwheat was lower than that of common buckwheat [48]. It is noteworthy
that human digestion is hugely different from that of rodents, such as rat and hamster, indicating
that these results need to be interpreted with caution and more studies are required to answer this
question [103]. In addition, the strong suppression of cholesterol by buckwheat protein products
could be ascribed to its effect on higher bile acid synthesis, and also a greater excretion of fecal bile
acids observed in rats, with the possibility that buckwheat protein products could possess some
bile acid-binding proteins [47,49]. It has been further demonstrated in vitro that digestion-resistant
peptides were largely responsible for bile acid binding activity of buckwheat protein digests and bile
acid elimination [104,105]. Consistent with this, Zhang and colleagues very recently further suggested
that Tartary buckwheat protein was one of the active ingredients to decrease plasma total cholesterol
concentration, mainly regulated by improving the excretion of bile acids by its effects on the gene
expression of hepatic CYP7A1 in an uptrend, but also preventing absorption of dietary cholesterol by
its effects on the gene expression of intestinal Niemann-Pick C1-like protein 1 (NPC1L1), acyl CoA:
cholesterol acyltransferase 2 (ACAT2), and ATP binding cassette transporters 5 and 8 (ABCG5/8) in
a downtrend [57]. Moreover, the composition of amino acids in dietary proteins might be another
important factor influencing blood cholesterol concentration, especially the ratio of lysine to arginine,
which is even lower in buckwheat protein than that of soy protein [51]. Thus, it has been speculated
that the cholesterol-lowering effect of buckwheat protein products observed may be ascribed to lower
lysine: arginine ratio [51]. However, this hypothesis did not support the results that plasma cholesterol
was unaffected with the addition of arginine in the diets [50].
It is well known that Tartary buckwheat seeds are a major source of rutin and quercetin [106].
Minor amounts of quercetin identified in Tartary buckwheat seeds are the result of rutin
degradation [107,108]. The possibility of buckwheat rutin being one of the active components
responsible for the suppressive effect on cholesterol concentrations cannot be eliminated. Buckwheat
is well known to contain high concentrations of rutin (estimated 1.14%), a unique high flavonoid
content compared with other common plant foods. Rutin has been shown to prevent the increase
of plasma total cholesterol and non-HDL cholesterol in rats or mice fed with a high cholesterol
or high fat diet [56,109–112]. However, in contrast to the results with rats and mice, serum total
cholesterol concentrations in day-care staff were found to be lower in response to consuming cookies
prepared from common or Tartary buckwheat, but no significant differences were detected between two
buckwheat groups, even though the rutin content in Tartary buckwheat seed was 30 to 150 times greater
than that in common buckwheat [32,113]. It has also been suggested that the cholesterol-lowering
effects seen in animal models may be partially attributable to the quercetin content in buckwheat.
In animal models (rat, rabbit, and mice) fed a high-cholesterol or high-fat diet, dietary quercetin
given has been demonstrated to lower serum total cholesterol concentration [114–116]. However,
the results regarding the effects of quercetin on cholesterol concentrations are controversial; several
studies have reported that quercetin intake had no significant beneficial effects on total, LDL or
HDL cholesterol and triglycerides [117–120]. The underling mechanisms of the quercetin on lipid
metabolisms may be accounted for by the inhibition of cholesterol synthesis in hepatocytes and also
the enzyme myeloperoxidase which was shown to oxidize lipoproteins [121–123].
4.7. Sensitivity Analysis
In the sensitivity analyses, removing individual studies systematically retained the statistical
significance of the effects of buckwheat on total cholesterol, supporting the stability of the observed
effects, but the effect on triglycerides was no longer significant possibly due to reduced statistical
power. This finding indicates that effects on triglycerides were not stable to sensitivity analysis, in
which individual studies were removed, thus, such analyses should be interpreted with more caution.
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4.8. Limitations
Several limitations of this review should be noted. Firstly, relatively few long-term randomized
and well-controlled human studies have directly investigated the effects of buckwheat intervention
on risk markers for CVD, including weight gain, blood pressure, fasting blood glucose, insulin and
lipids, and studies to date have been of short duration with small sample sizes. In order to support
the effects, further, more large-scale, long-term human intervention studies are required. Secondly,
there was considerable variability in study design between studies included in the meta-analyses,
with different study durations and dose of buckwheat consumed. These effects may be taken into
account in regression meta-analysis; testing the number of studies available for such analyses was
considered insufficient. Whilst the results from the studies were largely consistent, and removal of
individual studies in sensitivity analyses showed that no study overly impacted on the results; this
suggests that the results should be treated with caution. Thirdly, most animal studies performed to
date have analyzed the effect of individual molecular components or various buckwheat extracts on
cell lines and animal models. However, human beings consume entire buckwheat seeds (as flour in
products) instead of individual extracts, leading to uncertainty regarding whether the efficacy can be
extrapolated to human health without further evaluation. Finally, the bioactive compounds responsible
for buckwheat’s cardiovascular health still remain uncertain, and the mechanisms underlying the
effects were not fully elucidated.
5. Conclusions
In conclusion, even though the literature to date is limited and often inconsistent in terms of study
results, this review suggests that increased intake of buckwheat may lower CVD risk markers, including
glucose, total cholesterol and triglycerides. Therefore, buckwheat, being a gluten-free alternative to
some common grains, such as wheat, barley and rye, deserves to be a part of our daily diet. However,
it still remains unclear whether increased intake of buckwheat has significant impacts on some CVD
risk markers such as body weight and LDL cholesterol. There is increasing evidence that reduction in
some risk markers associated with CVD could be due to polyphenol (phytochemical), soluble fibre,
protein, rutin, quercetin and other components in the buckwheat, but it has not been fully elucidated
which bioactive compounds are responsible for the underlying effects. Further research, especially
large, well-powered, long-term human intervention studies, are required to further understand and
promote the role that buckwheat seeds can play in cardiovascular health.
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